Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

被引:1
|
作者
Wozniak, Ewelina [1 ]
Broncel, Marlena [1 ]
Wozniak, Agnieszka [1 ]
Satala, Joanna [1 ]
Pawlos, Agnieszka [1 ]
Bukowska, Bozena [2 ]
Gorzelak-Pabis, Paulina [1 ]
机构
[1] Med Univ Lodz, Dept Internal Dis & Clin Pharmacol, Lab Tissue Immunopharmacol, Lodz, Poland
[2] Univ Lodz, Fac Biol & Environm Protect, Dept Biophys Environm Pollut, Lodz, Poland
关键词
OXIDIZED PHOSPHOLIPID MODIFICATION; CARDIOVASCULAR RISK; REPAIR; ATHEROSCLEROSIS; MANAGEMENT; GUIDELINES; CHOLESTEROL; EZETIMIBE;
D O I
10.1038/s41598-024-52571-w
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal-dominant inherited disorder associated with atherosclerotic cardiovascular disease (ASCVD). HeFH subjects have a higher lipoprotein(a), i.e. Lp(a), concentration than the general population. Patients with FH are exposed to elevated levels of LDL from birth and ox-LDL may induce other oxidation pathways. The aim of the study was to determine the levels of markers of oxidative stress and DNA damage in patients with HeFH and describe the effect of Lp(a) on the resulting damage. Higher DNA damage was identified in patients with HeFH compared to the normolipidemic ones, and ASCVD was associated with greater damage. Oxidative stress markers were elevated in HeFH patients; however, only ox-LDL was higher in the ASCVD group and its level correlated with DNA damage. A positive correlation was found between DNA damage and Lp(a) concentration in the HeFH patients. Higher levels of Lp(a) were associated with greater DNA damage, especially in patients with HeFH and ASCVD. In HeFH patients, the optimal Lp(a) cut-off point associated with ASCVD is > 23.45 nmol/L, i.e. much lower than for the general population; however this cut-off point needs validation in a larger group of HeFH patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] HIGH LIPOPROTEIN(A) CHOLESTEROL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    Medeiros, A. M.
    Alves, A. C.
    Bourbon, M.
    ATHEROSCLEROSIS, 2019, 287 : E41 - E41
  • [42] Lipoprotein(a) in Familial Hypercholesterolemia
    Jacob, Erin O.
    Mcintyre, Adam D.
    Wang, Jian
    Hegele, Robert A.
    CJC OPEN, 2024, 6 (01) : 40 - 46
  • [43] Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolemia
    Bos, S.
    Vongpromek, R.
    Ten Kate, G-J R.
    Yahya, R.
    Verhoeven, A. J. M.
    Feyter, P. J.
    Kronenberg, F.
    Sijbrands, E. J. G.
    Van Lennep, J. E. Roeters
    Mulder, M. T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 754 - 754
  • [44] Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
    Hartgers, Merel L.
    Defesche, Joep C.
    Langslet, Gisle
    Hopkins, Paul N.
    Kastelein, John J. P.
    Baccara-Dinet, Marie T.
    Seiz, Werner
    Hamon, Sara
    Banerjee, Poulabi
    Stefanutti, Claudia
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (02) : 390 - 396
  • [45] Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia
    Urdal, P
    Leren, TP
    Tonstad, S
    Lund, PK
    Ose, L
    CYTOMETRY, 1997, 30 (05): : 264 - 268
  • [46] Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia
    Miltiadous, George
    Saougos, Vasilios
    Cariolou, Marios
    Elisaf, Moses S.
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2006, 36 (03): : 353 - 355
  • [47] EFFECTS OF FENOFIBRATE ON HIGH AND LOW-DENSITY LIPOPROTEIN METABOLISM IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    MALMENDIER, CL
    DELCROIX, C
    ATHEROSCLEROSIS, 1985, 55 (02) : 161 - 169
  • [48] Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
    Funabashi, Sayaka
    Kataoka, Yu
    Hori, Mika
    Ogura, Masatsune
    Doi, Takahito
    Noguchi, Teruo
    Harada-Shiba, Mariko
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (16):
  • [49] SERUM LIPOPROTEIN AND LYMPHOCYTE LDL RECEPTOR STUDIES IN PARENTS AND CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    JOHANSEN, KB
    FAERGEMAN, O
    ANDERSEN, GE
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1982, 42 (02): : 113 - 118
  • [50] Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia
    Shishikura, Daisuke
    Harada-Shiba, Mariko
    Michikura, Masahito
    Fujioka, Shimpei
    Fujisaka, Tomohiro
    Morita, Hideaki
    Kanzaki, Yumiko
    Hoshiga, Masaaki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2025, 32 (01) : 100 - 110